Intimation of receipt of the In-Principal Approval for the issue and allotment of warrants to promoters/promoters group on a preferential basis

07 August 2026 BSE Limited, National Stock Exchange of India Limited, Corporate Relationship Department The Listing Department Phiroze Jheejheebhoy Towers Exchange Plaza, 5th Floor Plot No.C/1, 'G' Block Dalal Street Bandra - Kurla Complex Mumbai - 400 001 Mumbai - 400 051 Scrip Code - 543308 Symbol - KIMS ISIN: INE967H01025 ISIN: INE967H01025 Subject: Intimation of receipt of the In-principle Approval from BSE Limited and the National Stock Exchange of India Limited for the issue and allotment of 77,02,182 (Seventy-Seven Lakh Two Thousand One Hundred and Eighty-Two) warrants fully convertible into equity shares of face value of Rs. 2/- each, to promoters/promoter group on a preferential basis. Ref: Application submitted on 17 June 2026 in terms of Regulation 28 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Dear Sir/Madam, Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“SEBI Listing Regulations”), we wish to inform you that the Company has received the in-principle approvals from BSE Limited (“BSE”) and the National Stock Exchange of India Limited (“NSE”) for the issue and allotment of 77,02,182 (Seventy-Seven Lakh Two Thousand One Hundred and Eighty-Two) warrants fully convertible into equity shares of face value of Rs. 2/- each to Dr. Abhinay Bollineni (Promoter), Mr. Adwik Bollineni (Promoter) and Bharas Ventures LLP (Promoter Group) on a preferential basis in accordance with applicable law. Copies of the ‘in-principle’ approvals are enclosed herewith. We request you to take the above information on record. Thanking you, Yours truly, For Krishna Institute of Medical Sciences Limited Nagajayanthi J. R Company Secretary & Compliance Officer Ref: NSE/LIST/55834 August 07, 2026 The Company Secretary Krishna Institute of Medical Sciences Limited Dear Sir/Madam, Sub: In - Principle approval under Regulation 28(1) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 We are in receipt of your application regarding In-principle approval for issue of 77,02,182 Equity shares of Rs. 2/- each pursuant to conversion of warrants issued on Preferential basis in terms of Regulation 28(1) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. In this regard, the Exchange is pleased to grant in-principle approval for the said issue subject to the Company fulfilling the following conditions: 1. Filing the listing application at the earliest from the date of allotment. 2. Receipt of statutory and other approvals and compliance of guidelines/regulations issued by the statutory authorities including SEBI, RBI, MCA, etc. 3. Compliance with all the applicable guidelines, regulations, directions of the Exchange or any statutory authorities as on the date of listing application. 4. Compliance of all conditions as per the SEBI (LODR) Regulations, 2015 as on date of listing, Companies Act, 1956 / Companies Act, 2013 and other applicable laws. 5. Submissions of documents as may be required by NSE and payment of applicable fees. Further, the company is advised to strengthen internal controls (to monitor trades being executed by the proposed allottees in the scrip of the company) before allotment of securities in order to avoid any non-compliances in respect of trades being executed by the allottees in contravention of provisions of Chapter V of SEBI (ICDR) Regulations. In this regard, a) The Company is advised to obtain an undertaking from the allottee(s) confirming that they shall not do intra-day trading in the scrip of the company or any sale in the scrip of the company till the allotment date of the security as required under SEBI (ICDR) Regulations. b) The Company may note that the responsibility/onus is solely on the Issuer company to verify the above (a) and ensure compliance with applicable provisions including Regulation 167(6) of SEBI ICDR regulations, 2018. c) The Company may also note that any non-compliances, if observed by the exchanges post the undertaking and verification by the Issuer company may impact the listing of such shares. Kindly note, this Exchange letter should not be construed as approval under any other Act /Regulation/rule/bye laws (except as referred above) for which the Company may be required to obtain approval from other department(s) of the Exchange. The Company is requested to separately take up matter with the concerned departments for approval, if any. This Document is Digitally Signed Signer: POOJA RISHIKESH PASHTE Date: Fri, Aug 7, 2026 18:27:03 IST Location: NSE Ref: NSE/LIST/55834 August 07, 2026 The Exchange reserves its right to withdraw its in-principle approval at a later stage if the information submitted to the Exchange is found to be incomplete/incorrect/misleading/false or in contravention of any Rules, Bye-laws and Regulations of the Exchange, SEBI (LODR) Regulations, 2015, Guidelines/ Regulations issued by statutory authorities, etc. Yours faithfully, For National Stock Exchange of India Limited Pooja Pashte Manager National Securities Depository Limited Central Depository Services Limited P.S. Checklist of all the further issues is available on website of the exchange at the following URL: https://www.nseindia.com/companies-listing/raising-capital-further-issuesmain-sme- checklist The National Stock Exchange of India (NSE) has announced the launch of NEAPS mobile application. The app can be downloaded from the App Store/ Play store with the name “NEAPS APP” This Document is Digitally Signed Signer: POOJA RISHIKESH PASHTE Date: Fri, Aug 7, 2026 18:27:03 IST Location: NSE